Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis

Immunoproteasome (IP) inhibition holds potential as a novel treatment option for various immune-mediated pathologies. The IP inhibitor ONX 0914 reduced T cell cytokine secretion and Th17 polarization and showed pre-clinical efficacy in a range of autoimmune disorders, transplant-allograft rejection,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Christian, Berger, Thilo, Groettrup, Marcus, Basler, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212513/
https://www.ncbi.nlm.nih.gov/pubmed/30416500
http://dx.doi.org/10.3389/fimmu.2018.02386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212513/
https://www.ncbi.nlm.nih.gov/pubmed/30416500
http://dx.doi.org/10.3389/fimmu.2018.02386

Ejemplares similares